JAGSNPHARM.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 06:00):

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine...

Stats
Today's Volume	13 379.00
Average Volume	36 144.00
Market Cap	8.59B
EPS	INR0 ( 2024-02-02 )
Next earnings date	( INR0 ) 2024-05-20
Last Dividend	INR5.00 ( 2023-08-21 )
Next Dividend	INR0 ( N/A )
P/E	34.94
ATR14	INR0.638 (0.20%)

Volume Correlation

Long: -0.26 (neutral)

Short: -0.26 (neutral)

Signal:(26.885) Neutral

Jagsonpal Pharmaceuticals Correlation

10 Most Positive Correlations
20MICRONS.NS	0.912
MUTHOOTFIN.NS	0.91
21STCENMGM.NS	0.902
DELPHIFX.NS	0.889
STAR.NS	0.887
ICICIPHARM.NS	0.887
KCP.NS	0.879
MEDICAMEQ.NS	0.877
IGPL.NS	0.876
PVP.NS	0.873

10 Most Negative Correlations
RAJRILTD.NS	-0.926
4THDIM.NS	-0.912
LTGILTBEES.NS	-0.876
SYMPHONY.NS	-0.869
SRTRANSFIN.NS	-0.84
ISMTLTD.NS	-0.833
GNA.NS	-0.832
SHRIRAMEPC.NS	-0.807
JSL.NS	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Jagsonpal Pharmaceuticals Correlation - Currency/Commodity

0.71
( moderate )

0.74
( moderate )

0.59
( weak )

0.77
( moderate )

0.72
( moderate )

-0.80
( strong negative )

Jagsonpal Pharmaceuticals Financials

Annual	2022
Revenue:	INR2.37B
Gross Profit:	INR1.44B (60.67 %)
EPS:	INR10.20

FY	2022
Revenue:	INR2.37B
Gross Profit:	INR1.44B (60.67 %)
EPS:	INR10.20

FY	2022
Revenue:	INR2.26B
Gross Profit:	INR1.30B (57.49 %)
EPS:	INR7.48

FY	2021
Revenue:	INR1.88B
Gross Profit:	INR1.07B (56.92 %)
EPS:	INR6.51

Financial Reports:

No articles found.

Jagsonpal Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Jagsonpal Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.51 - low (49.85%) | Divividend Growth Potential Score: 5.56 - Stable (11.22%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.75	2003-05-30
Last Dividend	INR5.00	2023-08-21
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR19.95	--
Avg. Dividend % Per Year	1.32%	--
Score	2.75	--
Div. Sustainability Score	4.51
Div.Growth Potential Score	5.56
Div. Directional Score	5.04	--

Next Divdend (Est)
(2024-07-05)

INR5.77 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.75

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.100	0.36%
2019	INR0.250	0.79%
2020	INR0.500	1.95%
2021	INR5.00	6.21%
2022	INR0	0.00%
2023	INR5.00	1.36%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RAILTEL.NS	Dividend Junior	2023-08-24	Semi-Annually	4	1.19%
KHAICHEM.NS	No Dividend Player	2023-07-21	Annually	5	0.32%
EMAMIPAP.NS	Dividend Junior	2023-09-05	Annually	3	0.56%
AJANTPHARM.NS	Dividend Knight	2023-08-04	Annually	23	0.57%
SUPRAJIT.NS	Dividend Junior	2023-09-18	Semi-Annually	20	0.45%
NAVNETEDUL.NS	Dividend Junior	2023-08-07	Annually	22	1.10%
HPIL.NS	Dividend Junior	2023-09-29	Annually	5	0.89%
CARERATING.NS	Dividend Knight	2023-07-06	Semi-Annually	12	1.81%
ROUTE.NS	Dividend Knight	2023-09-06	Semi-Annually	4	0.38%
LFIC.NS	Dividend Junior	2023-08-01	Annually	15	1.73%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.111	1.500	7.78	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.149	1.500	9.45	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	39.98	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.34	2.00	7.33	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.609	1.000	3.19	3.19	[0.2 - 0.8]
operatingProfitMarginTTM	0.144	1.000	9.13	9.13	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	35.45	1.000	6.52	0	[1 - 100]
returnOnEquityTTM	0.149	2.50	9.65	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
dividendYielPercentageTTM	1.512	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	3.35	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0636	1.000	-0.909	0	[0.1 - 0.5]
Total Score				5.56

Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.